Agreed end of year could be the kick start we need. Lets think...

Agreed end of year could be the kick start we need.

Lets think about what might happen.

We know safety for the GBM trial has been good. We have also been told that at lower dose levels there were signs of stabilising the disease in 76% of patients (low cohort size though). Remember, GBM is a very aggressive disease, so stabilisation of disease is a huge achievement, and no other solution other than surgery can achieve even that.
This is the first CarT that has shown any efficacy against a solid tumour cancer type. Thats huge. We also know that during pre clinical trials this CarT showed efficacy against 6 cancer types, 5 of which are solid tumour.

I would hope clinical signs of extension of life, disease control or better would get use well above 5c. We would have the first CarT to hit arm that has worked against solid tumours, and have a large potential market. It would also become eligible for accelerated approval. Thats worth far more than $30 milkion, and I think that would be enough to get market attention.

And then there is the NK cells ontop.